Pasar al contenido principal
  • Socios aprobados
  • Acerca de ELGA
    • Acerca de ELGA
    • Empleo
    • Eventos
  • Soporte
    • Planificación de laboratorio
    • Registrar un producto
    • Register Your Product (USA & Canada Only)
  • Contacto
  • U.S.A.
  • U.K.
  • Deutschland
  • France
  • Italia
  • Brasil
  • 日本
  • 中国
Inicio ELGA LabWater
  • Productos
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • Gama completa de productos ELGA
  • Aplicaciones
    • Análisis microbiológico
    • Bioquímica clínica
    • Cromatografía de gases
    • Cromatografía líquida
    • Electroquímica
    • Espectrofotometría
    • Espectrometría de masas
    • Espectroscopia atómica
    • Genética
    • Inmunoquímica
    • Requisitos generales de agua de laboratorio
  • Tecnologías
    • Carbón activado
    • Electrodesionización (EDI)
    • Filtración
    • Intercambio iónico
    • PureSure
    • Ultravioleta
    • Ósmosis inversa
  • Impurezas en el agua
    • Compuestos inorgánicos
    • Compuestos orgánicos
    • Gases disueltos
    • Microorganismos y bacterias
    • Partículas
  • Knowledge
    • Blog
    • Casos prácticos
    • Agua ultrapura
    • Manuales e informes técnicos
  • Productos
    • PURELAB
    • CENTRA
    • MEDICA
      • Hubgrade
      • MEDICA BIOX
    • BIOPURE
    • Gama completa de productos ELGA
      • PURELAB® Classic
  • Aplicaciones
    • Análisis microbiológico
    • Bioquímica clínica
    • Cromatografía de gases
    • Cromatografía líquida
      • Hochleistungsflüssigkeitschromatographie (HPLC)
    • Electroquímica
    • Espectrofotometría
    • Espectrometría de masas
    • Espectroscopia atómica
    • Genética
    • Inmunoquímica
    • Requisitos generales de agua de laboratorio
  • Tecnologías
    • Carbón activado
    • Electrodesionización (EDI)
    • Filtración
    • Intercambio iónico
    • PureSure
    • Ultravioleta
    • Ósmosis inversa
  • Impurezas en el agua
    • Compuestos inorgánicos
    • Compuestos orgánicos
    • Gases disueltos
    • Microorganismos y bacterias
    • Partículas
  • Knowledge
    • Blog
      • Analytical Chemistry
      • Clinical & Pharma
      • Cool Science
      • Environment and sustainability
      • Life in the lab
      • Purelab product design
      • Science of the future
      • Water Purity
      • Water in the lab
    • Casos prácticos
      • Abbott Diagnostics elige sistemas ELGA MEDICA en el sur de Asia
      • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
      • Argenta chooses DKSH New Zealand to deliver Ultrapure water in Animal Pharma
      • Clean Water for a Clean Future
      • LS Scientific & ELGA deliver UltraPure water to the NAFDAC Laboratory
      • Lifebrain Group chooses ELGA as water partner for new modern 24/7 PCR-COVID-19 laboratory in Vienna, Austria.
      • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
      • DASA: la mayor empresa de diagnóstico médico de Brasil
      • ELGA ayuda a los laboratorios de inmunoserología a maximizar el tiempo de actividad
      • Fondazione Telethon Continues to Choose ELGA Labwater as a Trusted Partner
      • La importancia del agua ultrapura de tipo 1+ para el desarrollo de medicamentos genéricos
      • Seleccionan MEDICA® Pro para los analizadores Siemens ADVIA® del City General Hospital
      • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
      • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
      • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
      • PURELAB® flex: un sistema de formación ideal para el método de investigación actual
      • Powering Cutting-Edge Gene Research
      • Sichere Reinstwasserversorgung für präzise Produkttests
      • Zentrale Reinstwasser-Aufbereitung für Analyser
      • ELGA LabWater and Beckman Coulter Join Forces
      • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
      • Descubrir los secretos de la Antártida con ayuda del agua ultrapura
      • Advancing Genetic Technologies
      • Cross Infection Control: Pure and Simple
      • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
    • Agua ultrapura
    • Manuales e informes técnicos
      • Pureza de agua de HPLC
      • HPLC en farmacia
      • Reducción del riesgo clínico
      • Sostenibilidad
  • U.S.A.
  • U.K.
  • Deutschland
  • France
  • Italia
  • Brasil
  • 日本
  • 中国
  • Política de privacidad
  • Términos y condiciones
  • Cumplimiento legal internacional
  • Patentes
  • Aviso legal
  • Inicio
  • Could Faecal Testing Help Personalise Cancer Treatment?
Analytical Chemistry
Water Purity

Could Faecal Testing Help Personalise Cancer Treatment?

22 Jun 2020
- by Dr Alison Halliday

Scientific Testing

A new study suggests that measuring short-chain fatty acids in the gut may offer a way to predict which cancer patients will benefit from immunotherapy.


Cancer therapies that target elements of the immune system – immunotherapies – are showing remarkable results for many patients. So-called ‘immune checkpoint inhibitors’ work by interfering with the mechanism that cancer cells use to evade destruction by the body’s immune system. Examples include nivolumab and pembrolizumab, which target a molecule on the surface of cells called PD–1.

Treating patients with immune checkpoint inhibitors can shrink tumours and improve survival rates, even for whom other therapies have failed. However, the response to these drugs varies widely from person to person – particularly for those with solid tumours.

If clinicians could predict who will benefit from cancer immunotherapies in advance, this would help spare many patients from the risk of unnecessary side effects. Defining the factors that can influence this variability in response will also improve our understanding of how these treatments work, identifying new opportunities for widening their effectiveness in the future.

The Gut Microbiome is a Suspect

Several studies have suggested that the population of microorganisms in our gut may influence the success of cancer immunotherapies. But the mechanisms behind this potential association remain unclear. One suspect are the short-chain fatty acids, which are the major end–products of gut microbiome–mediated metabolism. These molecules are thought to have wide-ranging effects on the whole body – including in modulating the immune response. 

In a new study, published in JAMA Network Open, scientists set out to explore whether short-chain fatty acids are associated with the clinical outcomes of patients with solid tumours treated with nivolumab or pembrolizumab.1

Evaluating Short-Chain Fatty Acid Concentrations

The researchers recruited 52 patients with solid tumours before they started treatment with nivolumab or pembrolizumab. They collected faecal and plasma samples and measured the concentrations of various short-chain fatty acids using ultra–high–performance liquid chromatography coupled with tandem mass spectrometry.

For these experiments, they used ultrapure water from an ELGA PURELAB® flex 5 water purification system, minimising the risk of introducing contaminants that may affect their results.

The scientists carried out scans to measure the size of the patients’ tumours at regular intervals over the study. They then carried out statistical analyses to evaluate if the levels of short-chain fatty acids were related to their response to treatment. They found that high concentrations of acetic acid, propionic acid, butyric acid and valeric acid in faecal samples – and isovaleric acid in plasma – were associated with patients living longer without their disease getting any worse. 

A Non–Invasive Test

This is the first study to identify a link between short-chain fatty acids and the effectiveness of PD–1 treatment for solid cancers. 

If these results are confirmed in larger studies, testing faecal samples from patients with solid tumours could offer a relatively simple way to predict who may benefit from nivolumab or pembrolizumab– paving the way to a more personalised approach to cancer immunotherapy in the future.

Why Choose ELGA LabWater?

ELGA’s expert engineers, chemists and scientists are at the forefront of technological innovation. We continue to introduce game-changing features to the laboratory water market.
 

Reference:

  1. Nomura M, et al. Association of Short–Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment with Nivolumab or Pembrolizumab in Patients with Solid Cancer Tumors. JAMA Network Open 2020;3(4):e202895


Dr Alison Halliday

After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

risk whitepaper

When lives are at stake, there is no margin for error. Your clinical analyser must receive a constant and reliable supply of CLRW. 

Find out how to protect your test results

                   Click Here

 

  • Enquiry
  • Consigue una cotización
  • Reserve una demo
  • Encuentre un socio aprobado

Enquiry

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Consigue una cotización

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Reserve una demo

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater US Headquarters

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
Reino Unido
Tel.: +44 (0) 203 567 7300
F: +44 (0) 203 567 7205

Sede central de ELGA LabWater

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
Reino Unido
Tel.: +44 (0) 203 567 7300
F: +44 (0) 203 567 7205

Casos prácticos

  • Abbott Diagnostics
  • Diagnóstico médico de DASA
  • Instituto Médico NeoDIN
  • Fundación del NHS de North Staffordshire
  • Escuela técnica de Olsberg

Recursos

  • Obtenga más información sobre el agua ultrapura
  • Manuales e informes técnicos
  • Tecnologías de purificación
  • Aplicaciones
  • Impurezas en el agua

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • Idioma
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Otros sitios de Veolia
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies

© VWS (UK) Ltd. comercializado como ELGA LabWater.2022-Todos los derechos reservados.
ELGA es la marca mundial de agua de laboratorio de Veolia.

  • Política de privacidad
  • Términos y condiciones
  • Cumplimiento legal internacional
  • Patentes
  • Aviso legal
Elga Veolia
TOP

© 2017 ELGA Veolia